title: Changes in secondary prevention of coronary artery disease in the post-discharge period over the decade 1997-2007. Results of the Cracovian Program for Secondary Prevention of Ischaemic Heart Disease and Polish parts of the EUROASPIRE II and III surveys.
abstract: BACKGROUND
  Both in the European and Polish guidelines, the highest priority for preventive cardiology was given to patients with established coronary artery disease (CAD). The Cracovian Program for Secondary Prevention of Ischaemic Heart Disease was introduced in 1996 to assess and improve the quality of clinical care in secondary prevention. Departments of cardiology of five participating hospitals serving the area of the city of Kraków and surrounding districts (former Kraków Voivodship) inhabited by a population of 1 200 000 took part in the surveys. In 1999/2000 and 2006/2007 the same hospitals joined the EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events) II and III surveys. The goal of the EUROASPIRE surveys was to assess to what extent the recommendations of the Joint Task Force of International Scientific Societies were implemented into clinical practice.
  
  
  OBJECTIVE
  To compare the quality of secondary prevention in the post-discharge period in Kraków in 1997/1998, 1999/2000 and 2006/2007.
  
  
  METHODS
  Consecutive patients hospitalised from 1 July 1996 to 31 September 1997 (first survey), from 1 March 1998 to 30 March 1999 (second survey), and from 1 April 2005 to 31 July 2006 (third survey) due to acute myocardial infarction, unstable angina or for myocardial revascularisation procedures, below the age of 71 years were identified and then followed up, interviewed and examined 6-18 months after discharge.
  
  
  RESULTS
  The number of patients who participated in the follow-up examinations was 418 (78.0%) in the first survey, 427 (82.9%) in the second and 427 (79.1%) in the third survey. The use of cardioprotective medication increased significantly: antiplatelets from 76.1% (1997/1998) to 86.9% (1999/2000) and 90.1% (2006/2007), beta-blockers from 59.1% (1997/1998) to 63.9% (1999/2000) and 87.5% (2006/2007), and ACE inhibitors/sartans from 45.9% (1997/1998) to 79.0% (2006/2007). The proportion of patients taking lipid lowering agents increased from 34.0% (1997/1998) to 41.9% (1999/2000) and 86.8% (2006/2007). Simultaneously, a significant improvement in the control of hyperlipidemia could be noted. In 2006/07, over 60% had a serum LDL cholesterol < 2.5 mmol/l. No significant change was found in the proportion of subjects with well-controlled hypertension or diabetes. In 2006/2007, elevated blood pressure was found in 46.6% of participants and glucose > 7 mmol/l in 13.4%. There was no significant change in smoking rates (16.3 vs. 15.9 vs. 19.2%). The proportion of obese patients increased reaching 33.9% in 2006/2007.
  
  
  CONCLUSIONS
  The implementation of CAD prevention guidelines into clinical practice over the decade from 1997/1998 to 2006/2007 changed significantly. The use of cardioprotective drugs increased largely but among risk factors a significant improvement could be found only in the case of hypercholesterolemia. No improvement in the control of hypertension and diabetes, no change in smoking rates and increasing prevalence of obesity suggest insufficient lifestyle modifications in CAD patients.
authors.affiliation: Department of Clinical Epidemiology and Population Studies, Institute of Public Health, Jagiellonian University Medical College, Krakow, Poland.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Pajak
authors.forename: Piotr
authors.initials: P
authors.lastname: Jankowski
authors.forename: Kalina
authors.initials: K
authors.lastname: Kawecka-Jaszcz
authors.forename: Sławomir
authors.initials: S
authors.lastname: Surowiec
authors.forename: Renata
authors.initials: R
authors.lastname: Wolfshaut
authors.forename: Magdalena
authors.initials: M
authors.lastname: Loster
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Batko
authors.forename: Leszek
authors.initials: L
authors.lastname: Badacz
authors.forename: Jacek S
authors.initials: JS
authors.lastname: Dubiel
authors.forename: Janusz
authors.initials: J
authors.lastname: Grodecki
authors.forename: Tomasz
authors.initials: T
authors.lastname: Grodzicki
authors.forename: Janusz
authors.initials: J
authors.lastname: Maciejewicz
authors.forename: Ewa
authors.initials: E
authors.lastname: Mirek-Bryniarska
authors.forename: Wiesław
authors.initials: W
authors.lastname: Piotrowski
authors.forename: Wanda
authors.initials: W
authors.lastname: Smielak-Korombel
authors.forename: Wiesława
authors.initials: W
authors.lastname: Tracz
mesh_terms: D000368:Aged; D002316:Cardiotonic Agents / Q000627:therapeutic use; D015897:Comorbidity; D003324:Coronary Artery Disease / Q000517:prevention & control / Q000628:therapy; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006937:Hypercholesterolemia / Q000453:epidemiology / Q000517:prevention & control; D006949:Hyperlipidemias / Q000453:epidemiology / Q000517:prevention & control; D008019:Life Style; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy; D009204:Myocardial Revascularization / Q000706:statistics & numerical data; D011044:Poland / Q000453:epidemiology; D055502:Secondary Prevention / Q000706:statistics & numerical data*
chemical_list: D002316:Cardiotonic Agents